Page 381 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 381
FRIDAY, APRIL 24, 2015 18:30 – 20:00
AbbVie Hall C (Plenary)
HCV special populations: Do they still exist?
Chairs:
Ira M. Jacobson, The United States
Stanislas Pol, France
HCV special patient populations: where have we come from?
Ira M. Jacobson, The United States
IFN-free for HCV: are GT1 cirrhotic patients still difficult-to-treat?
Heiner Wedemeyer, Germany
Is virologic cure now attainable for liver transplant recipients and HIV/HCV
co-infected patients?
Robert Brown, The United States
What are the IFN-free treatment options for HCV GT3 and GT4 infected
patients?
Ashley Brown, The United Kingdom
HCV special populations: where are we now and what challenges remain?
Stanislas Pol, France
INDUSTRY INFORMATION
Vienna, Austria • April 22–26, 2015 381
AbbVie Hall C (Plenary)
HCV special populations: Do they still exist?
Chairs:
Ira M. Jacobson, The United States
Stanislas Pol, France
HCV special patient populations: where have we come from?
Ira M. Jacobson, The United States
IFN-free for HCV: are GT1 cirrhotic patients still difficult-to-treat?
Heiner Wedemeyer, Germany
Is virologic cure now attainable for liver transplant recipients and HIV/HCV
co-infected patients?
Robert Brown, The United States
What are the IFN-free treatment options for HCV GT3 and GT4 infected
patients?
Ashley Brown, The United Kingdom
HCV special populations: where are we now and what challenges remain?
Stanislas Pol, France
INDUSTRY INFORMATION
Vienna, Austria • April 22–26, 2015 381
